Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Report of the scientific network Holimitox on succinate dehydrogenase inhibitor (SDHI) pesticides: new insights and challenges with an EcoHealth approach-presentations and round tables from the Holimitox day on November 7, 2024.

Environmental science and pollution research international·2026
Same author

Shared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson's diseases.

NPJ Parkinson's disease·2026
Same author

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Progress in modelling ATP13A2-linked neurodegeneration.

NPJ Parkinson's disease·2026
Same author

Correction: α-Synuclein modulates tau spreading in mouse brains.

The Journal of experimental medicine·2026

Related Experiment Video

Updated: Mar 25, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K

Targeting α-synuclein: Therapeutic options.

Benjamin Dehay1,2, Mickael Decressac3, Mathieu Bourdenx1,2

  • 1Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

Movement Disorders : Official Journal of the Movement Disorder Society
|March 2, 2016
PubMed
Summary
This summary is machine-generated.

New Parkinson's disease (PD) models using alpha-synuclein (αSyn) are advancing therapeutic strategies. Research focuses on blocking αSyn proteotoxicity via cellular clearance, including lysosomal-autophagic and proteasome pathways, and immunization.

Keywords:
Parkinson's diseaseanimal modelspropagationsynucleinopathyα-synuclein

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K

Related Experiment Videos

Last Updated: Mar 25, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alpha-synuclein (αSyn) aggregation is central to Parkinson's disease (PD) pathogenesis.
  • Novel PD models utilize viral vectors or toxic αSyn species to study neurodegeneration.
  • These models enhance understanding of PD mechanisms and preclinical therapeutic development.

Purpose of the Study:

  • To summarize recent advances in Parkinson's disease research focusing on αSyn.
  • To discuss emerging preclinical therapeutic strategies targeting αSyn.
  • To explore challenges and future directions in PD and synucleinopathy research.

Main Methods:

  • Review of current literature on αSyn-based PD models.
  • Analysis of therapeutic strategies targeting αSyn proteotoxicity.
  • Discussion of cellular clearance mechanisms (lysosomal-autophagic, proteasome) and immunization.

Main Results:

  • Viral vector and αSyn inoculation models provide insights into PD neurodegeneration.
  • Therapeutic strategies focus on inhibiting αSyn proteotoxicity.
  • Enhancing cellular clearance pathways and immunization are promising approaches.

Conclusions:

  • Advances in αSyn models offer significant promise for PD and synucleinopathy therapeutics.
  • Targeting proteotoxic mechanisms of αSyn is crucial for developing neuroprotective and restorative strategies.
  • Continued research efforts are vital for addressing ongoing challenges in PD treatment.